header logo image


Page 296«..1020..295296297298..310320..»

Research resuming on campuses – American Veterinary Medical Association

December 8th, 2020 8:00 pm

Chris Cramer, PhD, said in early November the University of Minnesota had reached about 80% of its research output prior to the pandemic.

Dr. Cramer is vice president for research and leader of a research group in the Department of Chemistry. He said the university is keeping lower numbers of people in laboratories and other research sites as well as restricting work involving human participants in uncontrolled environments, such as grade schools.

Otherwise, weve been pretty successful in bringing back most of the stuff that would require someone to come to campus, go to a field site, whatever it might be, he said.

Early this year, university research leaders described how their institutions delayed the start of new research, reduced staffing in research facilities, and added safety measures to ongoing studies.

By late spring, universities were publishing and implementing phased plans for resuming research, each with their own plans on how to protect investigators, participants, and the public.

Texas A&M Universitys Division of Research, for example, published in June plans for how investigators could resume research involving human participants and other clinical studies, as well as published overall research plans including an update as the fall semester began.

Johns Hopkins University officials published their JHU Return to Research Guidance on June 12, with limits on the time and activities allowed on campus, reduced capacity in laboratories, and added responsibilities for reducing transmission risks. The guidance states that some projects may proceed at a slower pace, and some studies may be lower priorities.

Isaac Pessah, PhD, associate dean and professor of molecular biosciences at the University of California-Davis School of Veterinary Medicine, said the university had been ramping up research after a substantial reduction early in the pandemic. The university maintained studies deemed essential, continued breeding irreplaceable animal lines, and maintained other animal populations while pausing new studies unrelated to COVID-19.

Starting June 1, UC-Davis officials allowed up to 33% of research personnel on-site for time-sensitive studies, with distancing and personal protective equipment requirements. Starting Oct. 30, the allowances expanded to all studies that need on-site access.

The next phase, whenever that may come, would allow two-thirds of research personnel on-site, resumption of field research, and expansion of all research activities.

Dr. Douglas K. Taylor is senior veterinarian in the Emory University School of Medicine Division of Animal Resources and a professor of pathology and laboratory medicine. He said in late October that Emorys research-use mouse populationthe bulk of the institutions research animal populationwas down about 15% from early March, when it was at an all-time high. The volume of research at the institution also was down about 15%.

We are certainly not back where we were in the beginning of the year, he said.

Dr. Joyce Cohen, associate director of animal resources at the Yerkes National Primate Research Center and associate professor in the Emory University School of Medicine Division of Psychiatry and Behavioral Sciences, said the primate research facility, in contrast, remained insanely busy.

We never really slowed down much during COVID, she said. We stopped doing new projects, but we didnt stop any ongoing projects with nonhuman primates.

Dr. Cohen said that, as the pause on new projects ended, more investigators started studies amid a torrent of ongoing research. The primate research center closed the fiscal year with more than $88 million in grant income, a record high.

Were having problems because of monkey shortages, she said.

In a typical year, Yerkes officials would be able to supplement their rhesus macaque population by buying more. But pharmaceutical companies are competing for all domestic sources of rhesus macaques because importation channels closed during the pandemic.

The Atlantic reported Aug. 31 that China provided 60% of the 35,000 monkeys imported to the U.S. in 2019 but halted those exports early this year.

Dr. Cohen said the center expanded its breeding colony, but each macaque can give birth only each spring, following a six-month gestation period. They become viable for research at 3 years old and optimal for studies at 5.

Dr. Taylor said the physical distancing rules at Emoryand most research institutions he knows oflimit the number of researchers in a procedure room. Dr. Cohen said all of Yerkes animal resource staff had returned with staggered shifts, and researchers have adjusted with unusual schedules to reduce laboratory occupancy.

We still have constraints with PPE, she said. Its still challenging. Weve been OK. Weve been able to get things, but its never a guarantee that well have enough face shields or enough masks.

Dr. Cramer said the pandemic also continues to hinder research among people whose work depends on travel, such as investigators in the humanities, social sciences, and geology. The university removed a previous restriction on domestic travel but continues to restrict international travel.

Veterinary researchers, in particular, struggled this year with deciding how to continue clinical trials involving pets and how they should protect pet owners, Dr. Cramer said. A Missouri resident might own a dog with cancer and travel to Minnesota to participate in a clinical trial, he said.

Should we have them do that, given the challenges associated with it for the individual? he said. And then, of course, how do you protect your staff and people in the veterinary clinic?

By early November, the volume of clinical trials in the veterinary clinic almost met the volume from before the pandemic, in part because travel is less uncertain, Dr. Cramer said.

In the spring, researchers and spokespeople at several universities indicated in interviews with JAVMA News they had reduced breeding of research animals, and a few depopulated mice in efforts to reduce the risks to human health. One institution sent livestock used in teaching laboratories to market earlier than planned.

Some news reports published at that time gave the impression research institutions were implementing widespread euthanasia of research rodents. Dr. Cohen said that, while some institutions euthanized research animals early in the pandemic, she thinks that was rare and institutions more often paused rodent breeding during the uncertain early months.

Dr. Pessah said research scientists across the UC-Davis campus, including the veterinary school, wonder whether the campus administration had been responsive to concerns about delays in studies unrelated to COVID-19.

But we are also very cognizant of safety as we move forward to ramp up, he said. So there are mitigating programs that have been put in place, especially for more junior faculty thatif your research has been delayed to the point where it has an impact on your ability to fulfill the missions in your grantsyou can apply for bridge funding to try to mitigate those delays.

The Office of Research leads that effort in cooperation with the deans, Dr. Pessah said. The amount available will depend on demand.

Most of the studies out of the School of Veterinary Medicine, though, met the definition of essential research because they deal with topics such as food animal health and food safety or require ongoing data collection to avoid massive losses, Dr. Pessah said.

Weve had a very open line of communication with all researcherswhether they use animals, cell lines, or a combinationto make sure that their essential research continues and their safety is maintained, he said.

As theoreticians, Dr. Cramer and the members of his research group work from home, in doing so following an order from Gov. Tim Walz that all people can work from home when possible. For other teams, the most challenging aspect tended to be deciding how to schedule workspace in ways that give people appropriate distance from one another while considering the space usually needed for their work.

When the fall semester began, though, new researchers needed training on laboratory techniques.

Sometimes, you need to be standing side by side with somebody, Dr. Cramer said. So, weve had to think about what things should be delayed in terms of training new people. Can we come up with techniques to deliver training without requiring folks to be too close to one another for too long a period?

For now, some of the trainers have relied on video-based training, whereas in-person instructors simply stood further away during their lessons and added plexiglass barriers, he said.

Though some researchers at the University of Minnesota developed COVID-19, none of those infections were traced to their workplaces or co-workers, Dr. Cramer said.

As for the research animal population, the University of Minnesotas mouse population was about 80% of its pre-pandemic total and climbing, Dr. Cramer said. Activity in the vivariums remained down to provide distance between researchers.

Dr. Taylor said that, for research institutions, business was returning to normal. He said researchers at Emory remained dedicated to their work and know it is important.

The work goes on, he said. The animals need to be taken care of. The research needs to move forward.

Read more from the original source:
Research resuming on campuses - American Veterinary Medical Association

Read More...

Study: Bartonella Infection Associated With Psychiatric Symptoms and Skin Lesions – NC State News

December 8th, 2020 8:00 pm

Bartonella bacteria are increasingly recognized as an emerging infectious disease threat. A new study by North Carolina State University researchers has found additional instances of Bartonella infection in humans who exhibited neuropsychiatric symptoms, a subset of whom also had skin lesions. This research adds to the body of evidence that not only can Bartonella infection mimic a spectrum of chronic illnesses including mental illness but also that dermatological symptoms may accompany infection.

Bartonella henselae is a bacterium historically associated with cat-scratch disease, which until recently was thought to be a short-lived (or self-limiting) infection. There are at least 30 different known Bartonella species, of which 13 have been found to infect humans. Improved methods for detecting Bartonella infection in animals and humans it is notorious for hiding in the linings of blood vessels and potentially the skin has led to the diagnosis of bartonelloses in patients with a host of chronic illnesses.

In 2019, Dr. Edward Breitschwerdt, Melanie S. Steele Distinguished Professor of Internal Medicine at NCState, published a case study involving an adolescent boy diagnosed with rapid onset schizophrenia, who had accompanying skin lesions. After Breitschwerdts research group documented Bartonella henselae infection, the patient received antimicrobial therapy and all neuropsychiatric symptoms resolved.

The new study is a follow-up to the 2019 work and is published in the journal Pathogens. Thirty-three participants suffering from neuropsychiatric symptoms ranging from sleep disorders and migraines to depression and anxiety enrolled in the study. Twenty-nine of 33 participants were found to have Bartonella infections based upon serology and enrichment blood culture polymerase chain reaction (PCR) testing. Twenty-four of the 29 Bartonella-positive participants (83%) reported the appearance of skin lesions during their illness.

Skin lesions ranged from cutaneous eruptions to red, irregular linear lesions randomly located on various parts of the patients body. Many of these lesions resembled striae distensae (stretch marks); however, typical risk factors for striae distensae, such as body building activities, obesity, pregnancy, prednisone treatment and other known disease associations, were either infrequently or not reported by study participants.

This research, a follow-up to our initial case report of Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS), was initiated to further investigate a possible association between neuropsychiatric illness, skin lesions and a bacterial infection of emerging biomedical importance, Breitschwerdt says. We hope that this research will enable physicians to suspect connections between disparate symptoms involving the nervous system and skin that could be associated with an underlying bacterial cause.

Breitschwerdt is the first and corresponding author of the research, which was supported by the Bartonella/Vector-Borne Diseases Research Fund at NCStates College of Veterinary Medicine. NCState research technician Julie Bradley, postdoctoral researcher Erin Lashnits, and research professor Ricardo Maggi, as well as dermatologist Paul Reicherter of the University of Missouri Kansas City Truman Medical Center, contributed to the work.

-peake-

Note to editors: An abstract follows.

Bartonella Associated Cutaneous Lesions (BACL) in People with Neuropsychiatric Symptoms

DOI: 10.3390/pathogens9121023

Authors: Ed Breitschwerdt, Julie Bradley, Ricardo Maggi, Erin Lashnits, North Carolina State University; Paul Reicherter, University of Missouri Kansas CityPublished: Online Dec. 7, 2020 in Pathogens

Abstract:Bartonella species are globally important emerging pathogens that were not known to infect animals or humans in North America prior to the human immunodeficiency virus (HIV) epidemic. Ongoing improvements in diagnostic testing modalities have allowed for the discovery of Bartonella species (spp.) DNA in blood; cerebrospinal fluid; and the skin of patients with cutaneous lesions, fatigue, myalgia, and neurological symptoms. We describe Bartonella spp. test results for participants reporting neuropsychiatric symptoms, the majority of whom reported the concurrent development of cutaneous lesions. Study participants completed a medical history, a risk factor questionnaire, and provided cutaneous lesion photographs. Bartonella spp. serology and Bartonella alpha proteobacteria enrichment blood culture/PCR were assessed. Within a 14-month period, 33 participants enrolled; 29/33 had serological and/or PCR evidence supporting Bartonella spp. infection, of whom 24 reported concurrent cutaneous lesions since neuropsychiatric symptom onset. We conclude that cutaneous lesions were common among people reporting neuropsychiatric symptoms and Bartonella spp. infection or exposure. Additional studies, using sensitive microbiological and imaging techniques, are needed to determine if, or to what extent, Bartonella spp. might contribute to cutaneous lesions and neuropsychiatric symptoms in patients.

See more here:
Study: Bartonella Infection Associated With Psychiatric Symptoms and Skin Lesions - NC State News

Read More...

New research marketing campaign part of CSU progress report to Board of Governors – Source

December 8th, 2020 8:00 pm

CSU System CFO Henry Sobanet provided an update on Gov. Jared Polis budget request including a $494 million general fund increase to public higher education to restore operating support for colleges and universities to the $825 million funding level of fiscal year 2020. If approved, the CSU System would receive $101.6 million. The governors request also allows up to a 3% increase in resident, undergraduate tuition rates.

Budget Each spring, typically in May, the Board finalizes the budget for the coming year. During the bimonthly meetings leading up to budget approval, the Board receives financial updates which model multiple scenarios reflecting updated projections of factors such as enrollment trends and the anticipated funding for higher education from the legislature.

The Board reviewed models for the Education and General Budget which assume state funding at the level of fiscal year 2020, a slightly greater than typical enrollment decline from fall to spring, and tuition increases of 0% or 3%. Given ongoing financial challenges, including those from COVID-19, the CSU models project a fiscal shortfall in the range of $19.7 million to $28.6 million. Consistent with the Governors budget request, there are no salary increases included in the current CSU budget modeling for FY2021. The Board continues to implement its multi-year strategy of managing the shortfall created by COVID-19. At the February meeting the Board will further discuss how to resolve a shortfall if those revenue projections hold steady after updates to enrollment figures and new state revenue projections.

Faculty Representative Report Professor Stephanie Clemons discussed CSUs nation-leading sustainability ranking and the successful in-person fall semester. Clemons is retiring, and Faculty Council will designate a new representative who will fill the role starting at the Boards February meeting.

Student Representative Report ASCSU President Hannah Taylor shared priorities that Associated Students of CSU are focusing on including: a petition drive for a ballot initiative to change the citys You+2 policy to ME+3; health initiatives including mass ordering of thermometers for students, mental health support, flu shot promotion; and support for Rams Against Hunger. Taylor also discussed ASCSUs mentor program for academics and a partnership with Rocky Mountain Student Media to do monthly fireside chats shared online on the CTV YouTube channel.

See the article here:
New research marketing campaign part of CSU progress report to Board of Governors - Source

Read More...

How to talk to pet owners about preventive care – Jill Lopez

December 8th, 2020 8:00 pm

Disease prevention is integral to practicing high-quality veterinary medicine. We aim to maintain pet health, yet we are often faced with sick animals whose owners were unaware of the importance of ongoingpreventive and wellness care. We need to focus on educating clients about the importance of disease prevention at every wellness appointment, but especially with new clients and at new pet appointments.

Improving Health and Quality of Life

Keeping pets happy and healthy is the ultimate goal of the veterinarian and pet owners partnership. Talk to the owner about how preventive care improves their pets longevity and quality of life. Consistently remind owners that preventive wellness checks are essential to meeting this goal. Communicate that unremarkable wellness exams are a sign of success, not wasted time or money.

Emphasize to clients that proactive disease screening is an important part of preventive care. Early diagnosis can simplify the treatment of many types of diseases, reducing costs and the long-term morbidity of many diseases. Overall, early intervention improves prognosis and the patients quality of life.

Preventive Care Benefits

Another important point of discussion is that disease prevention saves money. Even simple health issues can quickly become expensive if treatment has been delayed or postponed. Meanwhile, more serious health issues and emergencies are often a major financial burden to many clients. With wellness care, we can avoid some of these emergencies.

Reducing Zoonotic Risks

Furthermore, good preventive care that includes parasite control and vaccinations such as rabies and leptospirosis can reduce the incidence of zoonosis, avoiding the associated health impacts and healthcare costs.

Using Examples To Support the Benefits

Choosing an example to contrast the consequences of the disease with the simplicity of prevention or early intervention is a powerful way to educate the client on the benefits of preventive care. Some good examples include parvovirus, heartworm disease, leptospirosis, chronic kidney disease, or tumors.Picking ones that are most relevant to the individual patient create the most impact in the discussion.

If we can emphatically communicate the importance of disease prevention, we can see many more patients for regular wellness visits. This will provide us with better business, happy clients, and improved pet health.

Read more from the original source:
How to talk to pet owners about preventive care - Jill Lopez

Read More...

PET TALK: Seeing the signs: What to know about cherry eye in dogs – Houston Chronicle

December 8th, 2020 8:00 pm

Spotting a red bump in the corner of a pets eye is a concerning but not uncommon experience for many dog owners. Colloquially called cherry eye, this bump may be a prolapsed gland of the nictitans, also known as the third eyelid.

Dr. Sean Collins, a clinical assistant professor at the Texas A&M College of Veterinary Medicine, says that ophthalmologists dont entirely understand why the gland of the nictating membrane sometimes protrudes from its original position but it is believed to be a result of a weakness in the connective tissue responsible for holding the gland in the correct position.

This condition can happen to any breed of dog but is seen most commonly in certain breeds, including the American cocker spaniel, English bulldog, Lhasa apso, and the Pekinese, Collins said.

Pet owners who spot a red swollen mass in the inner corner of their pets eye, large or small, should bring it to their veterinarians attention promptly. In addition to causing irritation to the dog, this condition can have lasting consequences when left untreated.

Without correction, chronic prolapse can lead to conjunctivitis (pink eye) and ocular discharge (liquid coming from the eye), Collins said. It has also been shown that with correction, dogs are less likely to develop low tear production later in life.

Low tear production can result in multiple problems if left untreated. In addition to pain and decreased vision, corneal ulceration may also develop, which can become infected and result in a ruptured eye. This condition responds well to tear stimulant therapy in most cases, but lifelong medication is usually required.

Your veterinarian will be able to confirm whether your pet has cherry eye and can develop a treatment plan that works best to resolve cherry eye and reduce the potential for ocular issues as your dog ages.

Initial therapy may consist of topical anti-inflammatory therapy if local inflammation may be contributing to prolapse of the gland, he said. If a short course of medical therapy does not work or re-prolapse develops, surgical repositioning is indicated. There are numerous surgical techniques to reposition the gland with overall high success rates.

If surgical treatment is required, Collins stresses that this treatment will benefit your pet in both the short- and long-term.

Surgical repositioning is very important if initial medical therapy fails, as the gland is responsible for about 30-50% of the aqueous tear production in the dog, he said. We commonly see low tear production in the same breeds that develop a prolapsed gland of the nictitans. It has been shown that dogs with surgical repositioning of the gland have a lower chance of developing low tear production later on in life compared to those where the gland has been excised or remains chronically prolapsed.

Unfortunately, there are no known preventative measures to protect against cherry eye, Collins says. This condition can develop in both eyes, usually before the age of 2. The best way pet owners can protect their furry friend is to remain vigilant in monitoring their pets health and to bring concerns to their veterinarian promptly in case an issue does arise.

Pet Talk is a service of the College of Veterinary Medicine & Biomedical Sciences, Texas A&M University. Stories can be viewed on the web at vetmed.tamu.edu/news/pet-talk. Suggestions for future topics may be directed to editor@cvm.tamu.edu.

Continued here:
PET TALK: Seeing the signs: What to know about cherry eye in dogs - Houston Chronicle

Read More...

Pet talk: Seeing the signs: What to know about cherry eye In dogs – Marshall News Messenger

December 8th, 2020 8:00 pm

BRYAN-COLLEGE STATION Spotting a red bump in the corner of a pets eye is a concerning but not uncommon experience for many dog owners. Colloquially called cherry eye, this bump may be a prolapsed gland of the nictitans, also known as the third eyelid.

Dr. Sean Collins, a clinical assistant professor at the Texas A&M University College of Veterinary Medicine & Biomedical Sciences, says that ophthalmologists dont entirely understand why the gland of the nictating membrane sometimes protrudes from its original position, but it is believed to be a result of a weakness in the connective tissue responsible for holding the gland in the correct position.

This condition can happen to any breed of dog but is seen most commonly in certain breeds, including the American cocker spaniel, English bulldog, Lhasa apso, and the Pekinese, Collins said.

Pet owners who spot a red swollen mass in the inner corner of their pets eye, large or small, should bring it to their veterinarians attention promptly. In addition to causing irritation to the dog, this condition can have lasting consequences when left untreated.

Without correction, chronic prolapse can lead to conjunctivitis (pink eye) and ocular discharge (liquid coming from the eye), Collins said. It has also been shown that with correction, dogs are less likely to develop low tear production later in life.

Low tear production can result in multiple problems if left untreated. In addition to pain and decreased vision, corneal ulceration may also develop, which can become infected and result in a ruptured eye. This condition responds well to tear stimulant therapy in most cases, but lifelong medication is usually required.

Your veterinarian will be able to confirm whether your pet has cherry eye and can develop a treatment plan that works best to resolve the issue and reduce the potential for ocular issues as your dog ages.

Initial therapy may consist of topical anti-inflammatory therapy if local inflammation may be contributing to prolapse of the gland, he said. If a short course of medical therapy does not work or re-prolapse develops, surgical repositioning is indicated. There are numerous surgical techniques to reposition the gland with overall high success rates.

If surgical treatment is required, Collins stresses that this treatment will benefit your pet in both the short- and long-term.

Surgical repositioning is very important if initial medical therapy fails, as the gland is responsible for about 30-50% of the aqueous tear production in the dog, he said. We commonly see low tear production in the same breeds that develop a prolapsed gland of the nictitans. It has been shown that dogs with surgical repositioning of the gland have a lower chance of developing low tear production later on in life compared to those where the gland has been excised or remains chronically prolapsed.

Unfortunately, there are no known preventative measures to protect against cherry eye, Collins said. This condition can develop in both eyes, usually before the age of two. The best way owners can protect their furry friend is to remain vigilant in monitoring their pets health and to bring concerns to their veterinarian promptly in case an issue does arise.

Pet Talk is a service of the College of Veterinary Medicine & Biomedical Sciences, Texas A&M University. Stories can be found on the Pet Talk website. Suggestions for future topics may be directed to editor@cvm.tamu.edu.

Read the original:
Pet talk: Seeing the signs: What to know about cherry eye In dogs - Marshall News Messenger

Read More...

Global Veterinary Medicine Market to Get Expansion admist COVID 19, Scope With Advanced Technologies Top Key Players and Forecast 2020-2027 – The…

December 8th, 2020 8:00 pm

Global Veterinary Medicine MarketIndustry Trends and Forecast to 2028 New Research Report Added to Databridgemarketresearch.com database. The report width Of pages : 350 Figures: 60 And Tables: 220 in it. Global Veterinary Medicine Market describes complete industry Outlook with in-depth analysis. This report also Includes the complete analysis of each segment in terms of opportunity, market attractiveness index and growth rate, top players and new comers in industry, competitive landscape, sales, price, revenue, gross margin, market share, market risks, opportunities, market barriers, and challenges.key statistics on the market status. which give the clear idea about the product differentiation and an understanding of competitive landscape Globally.

Global Veterinary Medicine Market Research report comprises of a brief summary on the trends and tendency that may help the key market players functioning in the industry to understand the market and strategize for his or her Organisation expansion for this reason. This statistical surveying report examines the entire market size, market share, key segments, growth, key drivers, CAGR, historic data, present market trends And End User Demand, environment, technological innovation, upcoming technologies and the technical progress in the industry.

Veterinary medicine marketis expected to reach a market value of USD 45.6 billion by 2027 whilegrowat a potential rate of 7.15% in the forecast period of 2020 to 2027. Growing number of pet adoption will help in the growth of theveterinarymedicine market.

Get Sample Report + All Related Graphs & Charts @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-veterinary-medicine-market

Major players

The major players covered in the veterinary medicine market report are Merck & Co., Inc., Ceva, Vetoquinol S.A., Zoetis, BoehringerIngelheim International GmbH, Bayer AG, Elanco.,Nutreco N.V.,Virbac., Kindred Biosciences, Inc., BiogenesisBago, infocusrx., NEOGEN CORPORATION, Hester Biosciences Limited., Cargill, Incorporated., ADM Animal Nutrition,among other domestic and global players.

Patient Epidemiology Analysis

Veterinary medicine market also provides you with detailed Customization Available: Global Veterinary Medicine Market

market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Increasing prevalence of veterinary professionals, growing demand of pet insurance, increasing initiatives by the government as well as private regarding animal health, rising consumption of meat and mandatory vaccinations, growinglivestockpopulation as well as pet ownership rates will likely to enhance the growth of the veterinary medicine market in the forecast period of 2020-2027. On the other hand, increasing research and development for procedural advancement will further boost various opportunities that will lead to the growth of the veterinary medicine market in the above mentioned forecast period.

Rising number of counterfeit drugs, rising occurrences of various infections will likely to hinder the growth of the veterinary medicine market in the mentioned forecast period.

This veterinary medicine market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the veterinary medicine market scenario contactData Bridge Market Researchfor anAnalyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Grab Your Report at an Impressive 30% Discount! Please click Here @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-veterinary-medicine-market

Global Veterinary Medicine Market Scope and Market Size

Veterinary medicine market is segmented on the basis ofproduct, animal type, mode of delivery and end-use. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Veterinary Medicine Market Country Level Analysis

Veterinary medicine market is analysed and market size information is provided by country by product, animal type, mode of delivery and end use as referenced above.

For More Insights Get Detailed TOC @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-veterinary-medicine-market

North America dominates the veterinary medicine market due to prevalence of favourable government policies along with rising initiatives to improve animal health while the Asia-Pacific region is expected to grow at the highest growth rate in the forecast period of 2020 to 2027 because of expansion of manufacturing facilities and vaccination for livestock animals.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email @Corporatesales@databridgemarketresearch.com

Read the rest here:
Global Veterinary Medicine Market to Get Expansion admist COVID 19, Scope With Advanced Technologies Top Key Players and Forecast 2020-2027 - The...

Read More...

Endemic Corruption Is Reason Behind Alarming Wildlife Trafficking From Nigeria – Voice of America

December 8th, 2020 8:00 pm

ABUJA - Corruption has made Nigeria the biggest smuggler of ivory and pangolin scales from central and West Africa to Asia, according to a report by the Environmental Investigation Agency. The London-based group says in the past five years, Nigeria has been implicated in global seizures equating to 4,400 elephants and hundreds of thousands of endangered pangolins.

Aaron Olamilekan, a Nigerian wildlife advocate, spoke as he held a dead pangolin he bought from a group of local hunters arriving from a hunt on the outskirts of Abuja.

"They tell me why most of them hunt. It's based on poverty; there's no good job for them, there's no government support for them. So, they have no choice than to go into the wild," Olamilekan said.

The hunters sell the animals in exchange for cash.

But Olamilekan sometimes intercepts them, negotiates and rescues endangered species.

Animals returned to wild

He runs a sanctuary where he says animals can be resuscitated and nurtured before they're released into the wild.

"The ecosystem is being tampered with because all these animals have a role to play in our environment, so killing them will cause a future disaster," Olamilekan said.

Illegal hunting for trade is the major reason that endangered species such as elephants and pangolins are in constant decline.

Since 2015, Nigeria has been the main exit point for pangolin scales and elephant ivory from the continent to many parts of Asia, where they are prized for decorative purposes or their alleged but unproven medicinal uses.

Smugglers take ivory, scales

A recent report by the Environmental Investigation Agency (EIA) shows more than 30 tons of ivory and 167 tons of pangolin scales have been smuggled through the country in five years.

The EIA blames corruption by Nigerian border or port officials for the illegal trade. Shruti Suresh is a senior wildlife campaigner at EIA.

"Corruption which exists within certain public sectors is helping organized crime to thrive and traffic ivory, pangolin, and several other species." Suresh said. "We need political will at the highest level of government to prioritize this issue."

Nigeria is a member of several international conventions protecting endangered wildlife, including the Convention on International Trade of Endangered Species (CITES).

Laws rarely enforced

Nigerian authorities continue to pledge their commitment toward protecting wildlife even though laws meant to safeguard endangered species are rarely enforced.

The EIA wants Nigerian authorities to take stricter measures against poachers and smugglers, noting that uncontrolled trade during this period of the coronavirus pandemic could be potentially dangerous.

For the moment, wildlife advocate Olamilekan will be saving as many endangered animals as possible.

More here:
Endemic Corruption Is Reason Behind Alarming Wildlife Trafficking From Nigeria - Voice of America

Read More...

Vivos Inc to Present at The 13th Annual LD Micro Main Event Conference December 15, 2020 11:00 AM Eastern Standard Time – GlobeNewswire

December 8th, 2020 8:00 pm

Richland WA, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL``), Vivos Inc (RDGL), a company that has developed an Yttrium-90 based injectable brachytherapy device, for the treatment of tumors in animals and in humans, today announced that it will be presenting at the 13th annual LD Micro Main Event investor conference on Tuesday, December 15, 2020 at 8:00 AM PST / 11:00 AM EST. Mike Korenko, CEO of Vivos Inc., will be presenting to a live virtual audience.

Register here:ve.mysequire.com/

The Main Event will feature a new and unique format, with companies presenting for 10 minutes, followed by 10 minutes of Q&A by a panel of investors and analysts.

"The time has finally come to do something different in the virtual conference world. Lets see if we can pull off something that can be enjoyed by both executives and investors alike, stated Chris Lahiji, Founder of LD, now a wholly owned subsidiary of SRAX, Inc.

The Main Event will take place on December 14th and 15th, exclusively on the Sequire Virtual Events platform.

View Vivos Incs profile here http://ldmicro.com/profile/RDGL

View Vivos Incs site here: http://www.RadioGel.com

About Vivos Inc. (OTCQB: RDGL)

Vivos Inc. has developed an Yttrium-90 based injectable brachytherapy device, for the treatment of tumors in animals (Isopet) and in humans (Radiogel). Brachytherapy uses highly localized radiation to destroy cancerous tumors by placing a radioactive isotope directly inside the treatment area using the companys proprietary hydrogel technology. The injection delivers therapeutic radiation from within the tumor without the entrance skin dose and associated side effects of treatment that characterize external-beam radiation therapy. This feature allows safe delivery of higher doses needed for treating both non-resectable and radiation-resistant cancers.

Radiogel is a hydrogel liquid containing tiny yttrium-90 phosphate particles that may be administered directly into a tumor. The hydrogel is an yttrium-90 carrier at room temperature that gels within the tumor interstitial spaces after injection to keep the radiation sources safely in place. The short-range beta radiation from yttrium-90 localizes the dose within the treatment area so that normal organs and tissues are not adversely affected.

Radiogel also has a short half-life delivering more than 90% of its therapeutic radiation within 10 days. This compares favorably to other available treatment options requiring up to six weeks or more to deliver a full course of radiation therapy. Therapy can be safely administered as an out-patient procedure and the patient may return home without subsequent concern for radiation dose to family members.

The Isopet Solutions division used university veterinary hospitals to demonstrate the safety and therapeutic effectiveness for different animal cancers. Testing on feline sarcoma at the Washington State University was completed in 2018 and testing on canine soft tissue sarcomas at the University of Missouri was completed in 2019.

In 2018 the Company obtained confirmation from the FDA Center for Veterinary Medicine that Isopet is classified as a medical device according to its intended use and means by which it achieves its intended purpose. The FDA also reviewed the product labeling which included canine and feline sarcomas as the initial indications for use. The FDA does not require pre-market approval for veterinary devices so no additional approval is required. Following the demonstration phase, Vivos is able to generate revenue through the sale of Isopet to University animal hospitals and private veterinary clinics.

Isopet for treating animals uses the same technology as RadioGel for treating humans. The Food and Drug Administration advised using different product names in order to avoid confusion and cross-use.

CONTACT:

Vivos Inc.Michael K. Korenko, Sc.D.President & CEOMKorenko@RadioGel.com

About LD Micro/SEQUIRELD Micro began in 2006 with the sole purpose of being an independent resource to the microcap world. What started as a newsletter highlighting unique companies, has transformed into the pre-eminent event platform in the space. For more information, please visitldmicro.com.

The upcoming Main Event will be highlighting a new format that will benefit both executives and the investors tuning in from all over the globe.

In September 2020, LD Micro, Inc. was acquired by SRAX, Inc., a financial technology company that unlocks data and insights for publicly traded companies. Through its premier investor intelligence and communications platform,Sequire, companies can track their investors behaviors and trends and use those insights to engage current and potential investors across marketing channels. For more information on SRAX, visitsrax.comandmysequire.com.

ContactsInvestor Relations Contact:Brett MaasHayden IR, LLCbrett@haydenir.com646-536-7331

See the original post here:
Vivos Inc to Present at The 13th Annual LD Micro Main Event Conference December 15, 2020 11:00 AM Eastern Standard Time - GlobeNewswire

Read More...

Drake is selling a candle that smells like … Drake, and more of this week’s weirdest news – Napa Valley Register

December 8th, 2020 8:00 pm

Astronauts are harvesting fresh radishes grown in space, a delicious prospect that also could help seed food production efforts for longer-term missions to the moon and Mars.

The Advanced Plant Habitat cultivates radishes, a plant that is nutritious, edible and has a short cultivation time.

On Monday, NASA flight engineer Kate Rubins pulled out 20 radish plants grown in the space station's Advanced Plant Habitat, wrapping them in foil for cold storage until they can make the voyage back to Earth next year.

Radishes are the latest type of fresh produce to be successfully grown and harvested in zero gravity, joining "Outredgeous" red romaine lettuce, green lettuce, Chinese cabbage, lentils and mustard, according to a NASA fact sheet.

"I've worked on APH since the beginning, and each new crop that we're able to grow brings me great joy because what we learn from them will help NASA send astronauts to Mars and bring them back safely," said Nicole Dufour, the Advanced Plant Habitat program manager at NASA's Kennedy Space Center, in a news release.

Food for future space missions

Back on the ground, scientists at the Kennedy Space Center in Florida are growing radishes in a control group set for harvest on December 15. The researchers will compare the space-grown radishes to the veggies grown on Earth, checking on how space produce measures up on providing the minerals and nutrients astronauts need as they prepare for longer trips.

Meanwhile, astronauts will repeat the radish experiment in the heavens, planting and harvesting another round of radish crop to give scientists more data to draw from.

With their short cultivation time, radishes present potential advantages as a food source for future astronauts embarking on deep space missions in years to come. The radishes grow quickly, and they can reach full maturity in 27 days.

The root vegetables also don't require much maintenance from the crew as they grow.

astronaut and flight engineer Kate Rubins checks out radish plants growing on the space station as part of an experiment to evaluate nutrition and taste of the plants.

"Radishes provide great researchpossibilities by virtue of their sensitive bulb formation," said Karl Hasenstein, a professor of biology at the University of Louisiana and the principal investigator on the project, in a news release.

Researchers will analyze the effects of carbon dioxide on the radishes as well as how the vegetables acquire and distribute minerals, according to Hasenstein, who has run plant experiments with NASA since 1995.

Astronauts have grown 15 different types of plants on the station, including eight different types of leafy greens. And NASA has already tested more than 100 crops on Earth, identifying which candidates to try out next in space.

"Growing a range of crops helps us determine which plants thrive in microgravity and offer the best variety and nutritional balance for astronauts on long-duration missions," Dufour said.

Years of research with space crops

The latest experiments build upon ongoing research growing and harvesting plants in space.

Researchers at NASA began experiments using its Vegetable Production Systems growth chambers back in 2014 shortly after they were delivered to the space station.

Some of the early experiments with red romaine lettuce resulted in a paper, published this March in the journal Frontiers in Plant Science, showing that space lettuce was safe to eat.

In August 2015, NASA shared a video that features American astronauts Dr. Kjell Lindgren and Scott Kelly floating aboard the station, saying "Cheers" and eating the space-grown treat.

"Tastes good," Kelly said.

Getting space agriculture right matters because the nutrients in the prepackaged food that astronauts currently eat in space degrade over a period of time, NASA said.

Getting humans to Mars and back safely over a two- or three-year mission requires growing food along the way. That not only gives astronauts more of a vibrant supply of fresh nutrients on the voyage; it also serves an emotional need as they tend to crops that are both a figurative and literal taste of home, according to the agency.

The NASA Artemis program aims to land the first woman and next man on the moon in 2024, and to establish a sustained presence on the moon by 2028. From there, the agency will be poised to begin staging its next big leap, to Mars.

But before we make it to the red planet, we've first got to make a tasty green space salad.

CNN's Ashley Strickland contributed to this story.

Continued here:
Drake is selling a candle that smells like ... Drake, and more of this week's weirdest news - Napa Valley Register

Read More...

Insights on the Global Stem Cell Therapy Market 2020-2024: COVID-19 Analysis, Drivers, Restraints, Opportunities, and Threats – Technavio – Business…

December 8th, 2020 7:58 pm

LONDON--(BUSINESS WIRE)--The stem cell therapy market is expected to grow by USD 588.22 mn, progressing at a CAGR of almost 7% during the forecast period.

Click & Get Free Sample Report in Minutes

The increase in awareness of stem cell therapy is one of the major factors propelling market growth. However, factors such as the high cost of clinical trials will hamper the market growth.

More details: https://www.technavio.com/report/stem-cell-therapy-market-industry-analysis

Stem Cell Therapy Market: Type Landscape

Based on the type, the allogeneic transplants segment is expected to witness lucrative growth during the forecast period.

Stem Cell Therapy Market: Geographic Landscape

By geography, North America is going to have a lucrative growth during the forecast period. About 51% of the markets overall growth is expected to originate from North America. The US and Canada are the key markets for the stem cell therapy market in North America.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

Related Reports on Health Care Include:

Companies Covered:

What our reports offer:

Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Technavios in-depth research has direct and indirect COVID-19 impacted market research reports.

Register for a free trial today and gain instant access to 17,000+ market research reports.

Technavio's SUBSCRIPTION platform

Key Topics Covered:

Executive Summary

Market Landscape

Market Sizing

Five Forces Analysis

Market Segmentation by Type

Customer landscape

Geographic Landscape

Vendor Landscape

Vendor Analysis

Appendix

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Read the original post:
Insights on the Global Stem Cell Therapy Market 2020-2024: COVID-19 Analysis, Drivers, Restraints, Opportunities, and Threats - Technavio - Business...

Read More...

APAC Dry Eye Product Industry to 2027 – Adoption in Stem Cell Therapy Presents Opportunities – ResearchAndMarkets.com – Business Wire

December 8th, 2020 7:58 pm

DUBLIN--(BUSINESS WIRE)--The "Asia Pacific Dry Eye Product Market to 2027- Covid-19 Impact and Regional Analysis by product ( Artificial tears, Antibiotic Drops, Hormone Drops and Others); Type (OTC Drugs, Prescription Drugs);and Country." report has been added to ResearchAndMarkets.com's offering.

The Asia Pacific Dry Eye Product market is expected to reach US$ 1786.15 million by 2027 from US$ 1200.95 million in 2019. The market is estimated to grow with a CAGR of 5.3% from 2020 to 2027.

The growth of the market is driven by factors such as the growing the incidences and case of dry eye as well as rising the geriatric population across the globe. However, high significant amount of side effects of dry eye products and COVID-19 pandemic is likely to restrain the market growth to a certain extent.

Dry eye is a chronic syndrome and is a progressive depending upon the cause and severity. It is a condition when a person does not have tears to lubricate his or her eyes. Tears are an essential part of maintaining good health of the eye and assist in providing good vision. The syndrome is commonly seen among older people and is becoming common among people spending a long time in front of the computer. The factors that can cause dry eye include age, medications, environmental conditions, long term use of contact lenses. The conditions cannot be cured completely; however, it can be managed by using medical products.

So to treat such an unavoidable condition dry eye products and accessories being commonly used the products restores the water into the eye sack and lubrication takes up and condition retrieves. Now a days changing lifestyle among the people is the common cause of developing dry eye which ultimately boosts the demand for this segment product.

The products are been designed according to the need of a condition such as artificial drops, antibiotic drops, hormone drops.

Reasons to Buy

Market Dynamics

Drivers

Restraints

Opportunities

Future Trends

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/cy2oa7

Link:
APAC Dry Eye Product Industry to 2027 - Adoption in Stem Cell Therapy Presents Opportunities - ResearchAndMarkets.com - Business Wire

Read More...

Panacea of 21st century for ovarian rejuvenation – BioNews

December 8th, 2020 7:58 pm

7 December 2020

Assisted Conception Unit, Guy's Hospital, London

In ancient times, theriac, a medical concoction made by Greeks that was thought to cure all illnesses, had spread all over the then known world. It took months to prepare a proper theriac and that, of course, made it expensive. Only rich people could afford it. The recipe for theriac kept changing over time, depending on the availability of ingredients. In medieval times, it included ground mummy. In the Venetian Republic, in addition to viper flesh and opium, it included exudate from the castor sacs of mature beavers. Today, the theriac recipe has lost its magic and mystique. Nearly all ingredients are chemically defined, along with their specific applications. For example, beaver castoreum has 24 compounds, mostly ketones, phenols and alcohols. We use it mostly in the perfume industry, while Swedes use castoreum to flavour their Bverhojt schnapps.

The theriac of old may have been explained away; but does have a modern equivalent. Today, theriac is called mesenchymal stem cells(MSC). MSCs can cure almost anything, we are told. Just name it: osteoarthritis, COVID-19, autism, and infertility. Before all of you who struggle with fertility rush to your nearest purveyor of this new miracle treatment, take a moment to read here what we actually know about MSCs, how they work, and what they can do. If you then still believe that they are the solution to your problems, go for it (Madonna fixed her knee cartilage with stem cells, did she not?). Good luck to you. If you change your mind, you'll be saving several thousands of pounds, that might be better spent on your Christmas shopping.

MSCs are adult stem cells traditionally found in the bone marrow, but are also found in multiple tissues of the body. These cellsare multipotent; they can differentiate only into cells types originating from the same germ layer, contributing to the lymphatic, circulatory or musculoskeletal systems. If you delve into the scientific literature, you will find reports claiming that scientists have been able to transdifferentiate MSCs into cells of ectodermal and endodermal tissues, just because they were able to detect one or two of these cell lineage markers. However, their presence alone is insufficient evidence.

MSCs have gained popularity for several reasons: 1) They had no specific markers, and nobody could prove whether the cells are indeed MSCs or not; 2) conservative forces, fighting the use of human embryonic stem cell(hESC) for research and therapy, bestowed power on MSCs with little or no evidence at all. With no ethical strings attached, MSCs were presented as being as biologically powerful as hESCs. The Vatican was even organising MSC-related stem cell conferences; and 3) they can be easily isolated from bone marrow or adipose tissue and re-injected back into the same person in a different site, circumventing any legal or medical issues attached to transferring biological material between patients as long as the procedure was done at the required safety standards with no apparent intent to harm (intentional harm of a patient's bank account might be considered an acceptable exception).

After years of fiddling with MSCs and trying to understand what they can do and how they work, it seems that the idea that stem cells could differentiate and be used to replace damaged tissue did not work as we expected. When injected into a human, their life is short, and engraftment is generally low; most of the MSCs end up stuck in the capillary network of the lungs. Some of them find a home in damaged tissue. Numerous studies have shown that MSCs can modulate the progression of inflammation and maintenance of tissue homeostasis via an array of immunosuppressive factors, cytokines, growth factors and differentiation factors. MSCs are recruited to the site of inflammation and there, in response to inflammatory cytokines, they suppress the activation and function of various cells of the innate and adaptive immune systems via a different mechanism.

Their remarkable immunomodulatory properties are used in the treatment of severe systemic inflammatory disorders such as steroid-resistant acute graft-versus-host disease. What do these immunomodulatory properties have to do with fertility? How will they rejuvenate ovaries and revive the menstrual cycle?

For me, it is very difficult, if not impossible, to connect all the knowledge about MSCs with their application in fertility treatments. I am a stem cell scientist and I have worked with stem cells for more than 20 years. I have strong evidence-based reasons to argue that any stem cell therapy currently offered for fertility treatment would not work beyond a placebo effect.

I am also sure that many of you will have a different opinion.

Link:
Panacea of 21st century for ovarian rejuvenation - BioNews

Read More...

Winter can exacerbate arthritis pain: Heres how to deal with it – TheHealthSite

December 8th, 2020 7:56 pm

Cold weather can have a significant impact on your health, particularly for those who are suffering from arthritis. As the temperature drops, bones usually become stiff, inflexible and creaking, which can heighten discomfort in the joints, making life of people with arthritis troublesome. In fact, anyone who suffers from arthritis pain can sense and predict the change in weather. Also Read - Arthritis: Smoking and other bad habits that can be deadly for your joints

Not only the cold weather increase stiffness and joint pain, it can also lead to increased anxiety, depression and isolation for patients with arthritis. Also Read - Dont delay your arthritis pain, seek timely intervention

So, here are some tips to ease joint pain, maintain your bone health and stay happy during the winters. Also Read - 5 home remedies and tips to combat winter-induced pain and joint stiffness

Keep your aching hands, knees and legs warm with gloves, tights or leggings, and boots. Add extra layers of clothing, if needed and especially when you go out in winter. But make sure it doesnt restrict your movement. More layers of clothes work better at trapping the body heat than wearing thicker clothes.

Dehydration can make you more sensitive to pain, as revealed by a 2015 study published in Experimental Physiology. Water flushes toxins out of your body, which can help fight inflammation. Also, water helps keep your joints well lubricated. Whats more, drinking water before a meal can promote weight loss. Studies have found significant improvement in people with knee arthritis when they lost weight loss.

Many people tend to hibernate and laze around during the winters. But staying active is crucial for people living with arthritis. It can help ease pain, increase strength and flexibility, and boost energy. Doctors recommend adults with arthritis to do at least 150 minutes of moderate-intensity aerobic activity a week and two weekly sessions of strength training. Note: This advice is for those who have normal physical function and no other severe health conditions. If you want to avoid the winter chill, workout indoors.

A warm shower or soak in a tub, swimming in a heated pool, using heating pads, hot water bag, electric blankets these are some ways to reap the benefits of heat therapy. Heat can improve blood flow and help flush out pain-producing chemicals. It can also stimulate receptors in your skin that improve your pain tolerance. In addition, heat relaxes muscles, which in turn helps decrease spasms and reduce stiffness.

Less exposure to the sun makes it difficult to get enough vitamin D or sunshine vitamin in the winter. Studies have linked lower vitamin D levels with more severe clinical manifestations of rheumatic arthritis. Low vitamin D levels may also increase sensitivity to pain. Therefore, Vitamin D supplement is often recommended for arthritis patients. Talk to your doctor about your need for supplements. Meanwhile, you can add foods that contains vitamin D such as fatty fish like swordfish, mackerel, salmon, and tuna, and fortified products like orange juice, milk, and breakfast cereals to your diet.

Omega-3 fatty acids have anti-inflammatory properties, which can be beneficial for people who have an inflammatory type of arthritis.

A study published in the Annals of Rheumatic Disease in 2013 found that people with rheumatoid arthritis who took omega-3s supplements had a reduction in joint pain. Other studies suggest that omega-3s may help rheumatoid arthritis patients lower their dose of nonsteroidal anti-inflammatory drugs (NSAIDs). People with rheumatoid arthritis are at higher risk of heart disease, and omega-3s are known for their role in promoting heart health.

Fish oil is a rich source of omega-3 fatty acids. Plant-based sources of omega-3 fatty acids include avocado, flaxseeds, and walnuts.

Published : December 8, 2020 7:50 pm | Updated:December 8, 2020 8:04 pm

See original here:
Winter can exacerbate arthritis pain: Heres how to deal with it - TheHealthSite

Read More...

6 Things That Can Make Rheumatoid Arthritis Symptoms Worse – Yahoo Canada Shine On

December 8th, 2020 7:56 pm

Eat This, Not That!

One year ago, the holiday movie season was about to kick off, shopping centers were filled to the brink with people, and little kids were sitting on Santa's lap telling him what they wanted for Christmas. However, since COVID-19 became a threat to the health of Americans in early 2020, life as we know it has changed drastically. With a seemingly safe and effective vaccine just days to weeks away, many people are hoping there will be a return to normalcy within the next few months. On Tuesday, Dr. Anthony Fauci, the nation's leading infectious disease expert, spoke with The Wall Street Journal's Jonathan D. Rockoff, revealing when he expects life to be "normal" again. In short, it depends on the actions of you: the American people.. Read on, and to ensure your health and the health of others, don't miss these Sure Signs You've Already Had Coronavirus.We Could "Start Approaching Normality" by Q2/Q3, Says Dr. FauciWhile a vaccine will help us return to normalcy, it will only be effective if people actually get it. "I think that if we implement the vaccine program that I've just been describing with you, John, that we can do it in the back half of 2021," Fauci revealed."I believe if we get people vaccinated at a good rate, as we get into the open component where anybody can get vaccinated in April, May, June, July, I believe as we get to the end of the second quarter into the third quarter of the 2021, we can have a degree of protection community that we could start approaching normality in many of that over activities."So what will normal look like? It will involve "getting the CEOs"he mentioned CEOs because many were tuning into the Wall Street Journal livestream"to feel comfortable in getting people back in their establishments, having restaurants get in full capacity indoor, having some indoor functions that we can feel safe," such as theaters and places of entertainment and sports events.RELATED: 7 Tips You Must Follow to Avoid COVID, Say DoctorsNormality Depends on Enough People Taking the VaccineHowever, he reiterated that in order to get back to normal "towards the second half of 2021," we would need to "implement the vaccine program properly and aggressively." He sounds confident about the distribution. But there are hurdles, like convincing those who are anti-vaccine to take it. He's been promoting the safety of the vaccine to help spread the good word. "The data to prove it's safe and effective is seen first and only, and exclusively, by an independent data and safety monitoring board, not by the company, not by the federal government, but by an independent group of clinicians, vaccinologist immunologists, virologists, statisticians. They look at the data when the data shows, which it has, that the vaccine is safe and efficaciousIf you can get people to understand that, with an open mind, you will have essentially dissolved any reason that they might have for not getting vaccinated," he said. "And if they still don't want to get vaccinated, then I think there's something that we really can't overcomethat just inherently anti-vax."RELATED: Simple Ways to Avoid a Heart Attack, According to DoctorsHow to Stay Healthy During the PandemicUnfortunately, it is unlikely that COVID-19 will ever fully go away, and will forever linger. "I don't think we're going to eradicate it the way we did with smallpox, but I think we can do what we've done with polio and what we've done with measles and other vaccine-preventable diseases," he admitted.Until the vaccine takes into effect and there is herd immunity, public health measures will be crucial. Do everything you can to prevent gettingand spreadingCOVID-19 in the first place: Wear a face mask, get tested if you think you have coronavirus, avoid crowds (and bars, and house parties), practice social distancing, only run essential errands, wash your hands regularly, disinfect frequently touched surfaces, and to get through this pandemic at your healthiest, don't miss these 35 Places You're Most Likely to Catch COVID.

See the original post here:
6 Things That Can Make Rheumatoid Arthritis Symptoms Worse - Yahoo Canada Shine On

Read More...

When Admitted to the ICU, These Factors in Patients with Rheumatoid Arthritis May Increase Mortality Risk – DocWire News

December 8th, 2020 7:56 pm

A study examined factors that may be associated with poorer intensive care unit (ICU) outcomes among patients with rheumatoid arthritis (RA).

Immunosuppressive treatment for RA using glucocorticoids, conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), biologic disease-modifying antirheumatic drugs (bDMARDs), and targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs; e.g., JAK inhibitors) significantly improves disease activity and joint destruction; however, numerous comorbidities and complications, including infection, malignancy, and organ failure (cardiovascular disease [CVD], respiratory distress, and renal failure) remain associated with the increased mortality of RA patients compared with the general population, the researchers noted.

The retrospective study, published in BMC Rheumatology, consisted of 67 patients (47 were female) with RA admitted to the ICU for at least 48 hours between January 2008 and December 2017, who were assessed for 30-day mortality. Six patients were admitted to the ICU more than once during the study period, in which case only the first ICU admission was analyzed.

The median age at the time of admission was 70 years, and RA duration was 10 years. The five-year survival rate after ICU admission was 47%. The 30-day mortality rate was 22%, 90-day rate was 27%, and one-year rate was 37%. Most patients were admitted to the ICU due to infection (40%) and cardiovascular complications (24%). When in the ICU, the most common treatments were vasopressor (78%), mechanical ventilation (69%), and renal replacement (25%).

Two-thirds of the 30-day mortality patients died as a result of infection; factors associated with mortality were a significantly higher glucocorticoid dose, updated Charlsons comorbidity index (CCI), and acute physiology and chronic health evaluation (APACHE) II score.

According to laboratory data collected at admission, factors predictive of a significantly poorer prognosis were lower platelet number and total protein and higher creatinine and prothrombin time international normalized ratio (PT-INR). Upon multivariate analysis, factors that increased mortality risk following ICU admission were nonuse of csDMARDs, high updated CCI, increased APACHE II score, and prolonged PT-INR.

Read more:
When Admitted to the ICU, These Factors in Patients with Rheumatoid Arthritis May Increase Mortality Risk - DocWire News

Read More...

New Study Demonstrates Clinical Utility of PrismRA Test in Guiding Therapy Selection for Rheumatoid Arthritis Patients – GlobeNewswire

December 8th, 2020 7:56 pm

New findings from a clinical utility study in Rheumatology International

A new study published in Rheumatology International demonstrates clinical utility of PrismRA test in guiding therapy selection for rheumatoid arthritis patients.

Dr. James Mossell

Dr. James Mossell, DO is a Rheumatology Specialist in Tifton, GA and has over 31 years of experience in the medical field. He graduated from New York Osteopathic Medicine - New York medical school in 1989 and completed his fellowship in rheumatology at the University of Florida. He is affiliated with medical facilities such as the Tift Regional Medical Center, Coffee Regional Medical Center, and Crisp Regional Hospital. He is also a fellow with the American College of Rheumatology.

WALTHAM, Mass., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Scipher Medicine, a precision immunology company matching patients with the most effective therapy, today announced findings from a clinical utility study published in Rheumatology International that the PrismRA test can lead to major changes in prescribing behaviors. When test results indicated a likelihood of non-response, up to 89% of providers shifted their proposed therapy from tumor necrosis factor inhibitor (TNFi) to an alternative drug class based on the PrismRA score.

The majority of rheumatoid arthritis (RA) patients prescribed the worlds largest selling drug class, TNFi, do not adequately respond to treatment. PrismRA is a first-of-its-kind blood test that accurately predicts patients who will not have an adequate response to TNFi therapy so alternative effective therapy can be prescribed from day one, without first cycling through multiple TNFi drugs.

The results of this study clearly show that rheumatologists would change their medical management of RA patients if they had access to a predictive biomarker test like PrismRA, said James Mossell, Doctor of Osteopathic Medicine, Fellow of the American College of Rheumatology and an author of the study. Rheumatologists are eager to use precision medicine in complex autoimmune diseases such as RA and find high value in eliminating therapies that will likely fail in certain patients before selecting a more optimal targeted therapy.

The study surveyed 248 rheumatologists as to the clinical utility of a TNFi non-responder biomarker. A vast majority found the test easy to interpret and clinically useful, selection of TNFi therapy declined by 81% (from 79.8% to 15.3%) and 86% (from 79.8% to 11.3%) respectively when presented with a test result indicating a high or very high signal of non-response.

The clinical breakthrough enabled by PrismRA means more patients will be prescribed effective therapy sooner resulting in significantly improved health outcomes, said Alif Saleh, CEO of Scipher Medicine. We are pleased this study demonstrates the support of PrismRA by the rheumatology community.

About Scipher Medicine

Scipher Medicine, a precision immunology company, holds the fundamental belief that patients deserve simple answers to treatment options based on scientifically backed data. Leveraging our proprietary Network Medicine platform and artificial intelligence, we commercialize blood tests revealing a persons unique molecular disease signature and match such signature to the most effective therapy, ensuring optimal treatment from day one. The unprecedented amount of patient molecular data generated from our tests further drives the discovery and development of novel and more effective therapeutics. We partner with payers, providers, and pharma along the health care value chain to bring precision medicine to autoimmune diseases. Visit http://www.sciphermedicine.com and follow Scipher on Twitter, Facebook, and LinkedIn.

About PrismRA

PrismRA, a molecular signature test, is a revolutionary advancement bringing precision medicine to the treatment of rheumatoid arthritis, which affects 20 million patients globally. From a routine blood draw, the PrismRA test analyzes an individual's molecular signature, helping identify who is unlikely to adequately respond to TNFi therapy, the worlds largest selling drug class, so non-responders can be prescribed alternative effective therapy. Providers now have objective data to guide therapeutic decision-making and give patients the best chance of achieving treatment targets and improving clinical outcomes. For more information, please visit http://www.PrismRA.com

Media Contact:Alexander PettiAlexander@TakeOnCommunications.com201-978-4882

Scipher Medicine company contact:Andrea Mooreandrea.moore@scipher.com801.209.1175

Photos accompanying this release are available athttps://www.globenewswire.com/NewsRoom/AttachmentNg/63fce27f-c5e3-421b-a9c6-e57d9e2ffa99https://www.globenewswire.com/NewsRoom/AttachmentNg/3a651586-0fb6-433c-af6a-bb41baeb2b0c

See the rest here:
New Study Demonstrates Clinical Utility of PrismRA Test in Guiding Therapy Selection for Rheumatoid Arthritis Patients - GlobeNewswire

Read More...

New Screening Tool for Osteoporosis in Patients With Rheumatoid Arthritis – Rheumatology Advisor

December 8th, 2020 7:56 pm

Among patients with rheumatoid arthritis (RA), there is a correlation between the cortical thickness relative to the transverse diameter of third metacarpal bone and bone mineral density (BMD), suggesting this can be a promising screening tool for osteoporosis in this population, according to study results published in Bone.

Patients with RA are at increased risk for osteoporosis and fragility fractures. While dual-energy X-ray absorptiometry (DXA) is the gold standard for the diagnosis of osteoporosis, it is not widely available in many countries worldwide. Here the researchers sought to determine whether a screening index for BMD loss can be used as a substitute to the DXA method.

The Sharp/van der Heijde Scores were calculated using X-ray pictures of both sides of the hand. All patients with RA treated at Yoshii Hospital, Kochi, Japan, between April 2014 and September 2019, were subjected to the routine administration of X-ray pictures of the bilateral hands and feet at the first consultation and thereafter in order to calculate Sharp/van der Heijde Scores. Cortical thickness and the transverse diameter of the mid-portion of the metacarpal bone of the right middle finger were calculated and researchers determined the Cortical Thickness Ratio (CTR) as the cortical diameter relative to the transverse diameter. At the same time, BMD of the lumbar spine and femoral neck was measured.

Using the receiver operation characteristics (ROC) technique, the cut-off index of the CTR to the BMD was calculated. In addition, sensitivity, specificity, area under the curve, and the odds ratio for T-score < -2.5 were evaluated.

The cross-sectional study included 300 patients with RA (87.4% women, mean age 73.9 years). The mean transverse width of the third metacarpal bone was 7.3 mm and the thickness of the cortex was 2.0 mm, thus the average SD CTR was 0.2790.124.

There was a significant correlation between CTR and BMD in both the lumbar spine and femoral neck according to DXA testing.

In ROC analysis, the cut-off index of the CTR was 0.25 for the lumbar spine and femoral neck. For the lumbar spine, the sensitivity was 67.9% and the specificity was 83.0%, with an area under the curve of 0.78, and an odds ratio of 4.17 (95% CI, 2.51-6.92). For the femoral neck, sensitivity was 76.1%, specificity was 81.6%, the area under the curve was 0.81 with an odds ratio of 4.90 (95% CI, 2.75-8.73).

The index was examined in treatment nave patients in order to eliminate confounding of drug interventions, and the data suggested the CTR is a potential useful tool for the initial screening of osteoporosis for patients who are nave for osteoporosis and RA treatment.

[T]he CTR may be a strong candidate marker for screening for osteoporosis in patients with RA with the index less than 0.25. These findings may provide physicians with the diagnosis of osteoporosis in patients with RA, concluded the researchers.

Yoshii I, Akita K. Cortical thickness relative to the transverse diameter of third metacarpal bone reflects bone mineral density in patients with rheumatoid arthritis. Bone. 2020;137:115405. doi:10.1016/j.bone.2020.115405

Read more:
New Screening Tool for Osteoporosis in Patients With Rheumatoid Arthritis - Rheumatology Advisor

Read More...

Merete Lund Hetland: A cross country collaboration to assess the benefits and harms biological therapies for early rheumatoid arthritis – The BMJ -…

December 8th, 2020 7:56 pm

The Scandinavian countries may look rather similar when watching from a distance. However, if you zoom in on details, the differences become manifest.

This has been a returning truth in the more than ten years that the NORD-STAR collaboration has been running.

Initially, we saw the similarities: All countries (including the Netherlands, which joined the collaboration half-way through) had a history of high quality research in the field of rheumatoid arthritis and an idea of how to treat this debilitating and destructive inflammatory disease best. Investigator-initiated trials such as Fin-RACo and Neo-RACo (Finland), Swe-fot (Sweden), ARCTIC (Norway), CIMESTRA and OPERA (Denmark) and BeSt (The Netherlands) have contributed important knowledge to the field. Despite the modest sizes of our countries, our national quality registries (ARTIS, DANBIO, ICEBIO, NORDMARD, ROB-FIN) have informed clinicians around the world about treatment outcomes for real world patients with inflammatory arthritis. Moreover, in all countries biological drugs with different modes of action were widely available due to a tax-paid system for reimbursement.

Despite our previous research at the national level, we were stuck with an important, unanswered clinical question: What are the benefits and harms of the different biological therapies compared with active conventional treatment in patients with early rheumatoid arthritis?

The question had multiple aspects: The shorter term ability of the different therapies to induce remission was key. However, longer term results regarding the prevention of joint damage and safety profile were also important. Would there be differences in the flare rates between the drugs if treatment was de-escalated? Would spin-off projects based on the study biobank pave the way for more tailored treatments?

A cross-national collaboration was needed to answer these questions with sufficient statistical power. For our investigator-initiated trial, we needed more than 800 treatment-naive patients randomized to four different treatments, turning our study into one of the largest ever in rheumatoid arthritis.

This was when the differences between our countries became evident. Defining the active conventional therapy was a hard nut to crack in the planning of the design. Despite very similar EU-based legislation across the countries, bureaucratic obstacles challenged the approval from ethics, medical and data authorities. Securing public funding for the study infrastructure was an important milestone in the early phases, as was the willingness of two of three companies to provide us with free study drug.

We are proud to present the first results in The BMJ. Our 24-week results highlight the efficacy and safety of active conventional treatment based on methotrexate combined with corticosteroids, with nominally better results for the biologic abatacept.

The NORD-STAR research network has solved challenges, coped with frustrations, shared the joy and excitement during the various phase of the project. Ten years so far, and probably ten more years before we have the last results.

We believe the currentand futureresults from the NORD-STAR trial and spin-off projects will provide the medical community with important insights on how to best care for patients with early rheumatoid arthritis.

Merete Lund Hetland, Professor in Rheumatology, Consultant, and Head of the DANBIO steering committee, Copenhagen Center for Arthritis Research (COPECARE) and DANBIO, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark.

Competing interests: Please see research paper for more details.

Read the original here:
Merete Lund Hetland: A cross country collaboration to assess the benefits and harms biological therapies for early rheumatoid arthritis - The BMJ -...

Read More...

Baricitinib: Doctors Are Skeptical of This Covid-19 Drug From Eli Lilly – The New York Times

December 8th, 2020 7:56 pm

In mid-November, an arthritis drug with a tricky name hit a pandemic milestone then slipped back into relative obscurity.

The drug, baricitinib, was granted an emergency authorization by the Food and Drug Administration to treat a subset of hospitalized Covid-19 patients in combination with another medication, the antiviral remdesivir. It is one of only a handful of treatments to have earned the agencys green light.

But baricitinibs reception by the medical community has been lukewarm. It doesnt work all that well, for one thing, and comes with side effects, such as blood clots. And at a cost of roughly $1,500 per patient, many doctors dont know when it would make sense to use the drug, which might have overlapping roles with cheap and widely available steroids like dexamethasone.

In a clinical trial sponsored by the National Institutes of Health, hospitalized Covid-19 patients treated with baricitinib and remdesivir recovered one day faster than patients who had received remdesivir alone.

I think its really a nothing burger, said Dr. Ilan Schwartz, an infectious disease physician at the University of Alberta. Were talking about adding a drug that reduces the time to clinical improvement by one day, in a disease that takes weeks to recover.

These results, which were announced through a series of news releases by drugmaker Eli Lilly, have yet to be published in a peer-reviewed scientific journal. Kristen Porter Basu, a spokeswoman for the company, wrote in an email that a more detailed analysis would be published very soon.

When an emergency authorization has been released but the data have not, doctors are caught in a difficult place, said Dr. Manuela Cernadas, a critical care physician at Brigham and Womens Hospital in Boston. Its not entirely clear where this drug fits in our armamentarium of drugs were comfortable using.

Baricitinib is a repurposed arthritis treatment that, like a steroid, dampens inflammation, which, in severe cases of Covid-19, can spiral out of control and destroy healthy tissues. The drug acts like a molecular muffler, preventing the cells from responding to alarm signals that could make the bodys immune response spiral out of control.

The N.I.H. trial was designed to test whether baricitinib could boost the benefits of remdesivir, now the standard of care for Covid-19 patients. Remdesivir by itself speeds recovery by several days. The researchers found that the addition of baricitinib clipped an additional day off a patients recovery time and kept a few extra people off ventilators. But these and other results largely failed to impress experts, many of whom said the drug would need to have far bigger benefits to outweigh its price tag and potential harms.

It seems more incremental than blockbuster, said Dr. Taison Bell, a critical care physician at the University of Virginia, who was involved in the clinical trial. Although Dr. Bell described baricitinib as a reasonable addition to the Covid treatment toolbox, and even deserving of an emergency approval, I dont think its a game changer, he said.

Still, the findings were enough to convince the F.D.A., which issued an emergency authorization on Nov. 19. The drug is now allowed to be paired with remdesivir, but only to hospitalized patients who need supplemental oxygen, mechanical ventilation or other breathing support.

The agencys limited clearance aligns with the subset of patients in the N.I.H. trial who benefited the most from the dual drug combo, said Dr. Andre Kalil, an infectious disease physician at the University of Nebraska Medical Center and one of the lead researchers on the trial.

But this same population of patients people sick enough to need some form of breathing support would also be great candidates for steroids like dexamethasone, said Dr. Phyllis Tien, an infectious disease physician at the University of California, San Francisco.

Dexamethasone, unlike baricitinib, has been shown in studies to curb mortality in severely sick Covid-19 patients. A generic drug, its also cheap, costing cents or dollars per day of treatment, and has for months been a part of the coronavirus treatment playbook.

Im asking myself, Who would I think about using baricitinib in, over dexamethasone? Dr. Tien said.

But Dr. Boghuma Kabisen Titanji, an infectious disease physician at Emory University who pioneered early studies of baricitinib against the coronavirus, offered a more sobering perspective on dexamethasone. Steroids are blunt knives, she said, quashing inflammation on a broader scale than drugs like baricitinib do. Thats why steroids come with a host of unwanted side effects, including exacerbating conditions like diabetes or osteoporosis, she said.

The family of drugs that includes baricitinib, on the other hand, may offer more therapeutic precision, Dr. Titanji said. Theres also been some evidence that baricitinib might be able to block the coronavirus from entering cells.

Confused by the terms used about how to treat Covid-19?Let us help:

Still, baricitinib comes with its own problems, such as raising the risk of blood clots already an issue in many cases of Covid-19. That does give you pause, Dr. Cernadas said.

Both baricitinib and dexamethasone also blunt immune function, increasing the likelihood that other viruses or bacteria might infiltrate the bodies of the people theyre used in. But of the two, dexamethasone is the devil you know, said Dr. Lauren Henderson, a pediatric rheumatologist at Boston Childrens Hospital. I would probably not turn to baricitinib as a first line.

Dr. Tien and other experts echoed this sentiment, saying they would be likely to choose dexamethasone over baricitinib when treating someone with a serious case of Covid-19, unless there was an obvious reason their patient might respond poorly to steroids.

A head-to-head comparison between baricitinib and dexamethasone might clarify which patients would be better off taking one drug over another. At the end of November, the N.I.H. announced a trial that will compare outcomes between hospitalized Covid-19 patients who receive either a combination of remdesivir and dexamethasone, or a combination of remdesivir and baricitinib. But Dr. Schwartz and others raised ethical concerns about this trial, which he said would by definition deprive some patients of a lifesaving steroid therapy.

Eli Lilly is also running a trial to study the effects of baricitinib on its own in hospitalized patients. In this study, which isnt likely to finish until next summer, all participants will receive dexamethasone.

Link:
Baricitinib: Doctors Are Skeptical of This Covid-19 Drug From Eli Lilly - The New York Times

Read More...

Page 296«..1020..295296297298..310320..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick